Evidence map›Paper›PMID 36001200›Full record

ReviewCardiovascular drugs and therapy2024

A Comprehensive Review of the Pleiotropic Effects of Ticagrelor.

Jeffrey Triska, Neil Maitra, Matthew R Deshotels, Faris Haddadin, Dominick J Angiolillo, Gemma Vilahur, Hani Jneid, Dan Atar, Yochai Birnbaum

Abstract readReview
PubMed Publisher
In one paragraph

Review in Cardiovascular drugs and therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
3.0field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 18 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. The Signaling Pathway of the ADP Receptor P2YInternational journal of molecular sciences · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 3 countries.

Jeffrey TriskaThe Department of Medicine, Baylor College of Medicine, Houston, TX, USA. jeffrey.triska@bcm.edu.ORCID 0000-0003-4476-7994
Neil MaitraThe Department of Medicine, Baylor College of Medicine, Houston, TX, USA.
Matthew R DeshotelsThe Department of Medicine, Baylor College of Medicine, Houston, TX, USA.
Faris HaddadinThe Section of Cardiology, Baylor College of Medicine, Houston, TX, USA.
Dominick J AngiolilloDivision of Cardiology, University of Florida College of Medicine, Jacksonville, FL, USA.
Gemma VilahurCardiovascular Program, Research Institute Hospital de La Santa Creu I Sant Pau, IIB-Sant Pau, Barcelona, Spain.
Hani JneidDepartment of Medicine, Section of Cardiology, University of Texas Medical Branch, Galveston, TX, USA.
Dan AtarThe Department of Cardiology, Oslo University Hospital Ulleval, Oslo, Norway.
Yochai BirnbaumThe Section of Cardiology, Baylor College of Medicine, Houston, TX, USA.
Baylor College of Medicine · USInstituto de Salud Carlos III · ESOslo University Hospital · NOThe University of Texas Medical Branch at Galveston · USUniversity of Florida · US

Funding

John S. Dunn Foundation B2017/BMD-3738
6 · The paper itself

Abstract

aimsThis review summarizes the findings of preclinical studies evaluating the pleiotropic effects of ticagrelor. These include attenuation of ischemia-reperfusion injury (IRI), inflammation, adverse cardiac remodeling, and atherosclerosis. In doing so, it aims to provide novel insights into ticagrelor's mechanisms and benefits over other P2Y METHODS AND

resultsA comprehensive review of the preclinical literature demonstrates that ticagrelor protects against IRI in the setting of both an acute myocardial infarction (MI), and when MI occurs while on chronic treatment. Maintenance therapy with ticagrelor also likely mitigates adverse inflammation, cardiac remodeling, and atherosclerosis, while improving stem cell recruitment. These effects are probably mediated by ticagrelor's ability to increase local interstitial adenosine levels which activate downstream cardio-protective molecules. Attenuation and augmentation of these pleiotropic effects by high-dose aspirin and caffeine, and statins respectively may help explain variable outcomes in PLATO and subsequent randomized controlled trials (RCTs).

conclusionMost RCTs and meta-analyses have not evaluated the pleiotropic effects of ticagrelor. We need further studies comparing cardiovascular outcomes in patients treated with ticagrelor versus other P2Y

Indexed as

Purinergic P2Y Receptor AntagonistsTicagrelorAdenosineAnimalsAtherosclerosisHumansInflammationMyocardial InfarctionMyocardial Reperfusion InjuryAdenosinePurinergic P2Y Receptor AntagonistsTicagrelorAspirinCoronary artery diseaseIschemia–reperfusion injury, Myocardial infarctionP2Y12 inhibitorPleiotropic effectsSystematic reviewTicagrelor

Identifiers

PMID36001200
OpenAlexW4293117567

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.